Zihuai He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zihuai He has a total of 300 co-authors. Here are the top co-authors by number of shared publications:
- Yann Le Guen
Stanford University
15 shared publications Hua Tang
Department of Genetics Stanford University Stanford California USA
8 shared publications- Michael E. Belloy
Washington University in St. Louis
8 shared publications Xiaoxia Liu
Department of Biomedical Informatics, Jacobs School of Medicine and Biomedical Sciences University at Buffalo Buffalo New York USA
8 shared publicationsMichael E. Belloy
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94305, USA
7 shared publicationsIuliana Ionita-Laza
Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, 10032, USA
6 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in Research Square
Disease aging clocks in the plasma proteome stratify risk and track preclinical progression
Aging is the strongest risk factor for most chronic diseases, yet people of the same chronological age differ in how far disease processes have advanced. Existing plasma proteomic clocks estimate chronological age, or the age of a single organ, but none targets the pathway from aging to a specific disease. Here we developed disease aging clocks by deriving the plasma proteomic composite that maximizes the age-mediated component of disease risk and applied the framework to 31 age-related diseases in 44,526 UK Biobank participants. The resulting disease age gap separated 10-year incidence up to 20-fold among individuals of the same chronological age, and each additional year of gap raised the hazard of type 2 diabetes by 24%, chronic kidney disease by 21% and Alzheimer′s disease (AD) by 17%. Among participants who went on to develop disease, the gap was larger closer to diagnosis in 19 of 20 diseases, indicating that it reports preclinical stage rather than fixed susceptibility. Across these 20 diseases, 56% of the gap was orthogonal to chronological and organ-specific clocks. Applied without refitting to Stanford Alzheimer′s Disease Research Center participants (n=501), the AD clock was elevated in AD and Lewy body disease but not Parkinson′s disease, and tracked plasma biomarkers, cognition and neuroimaging features. Disease aging clocks provide a blood-based measure of the stage of a specific aging-to-disease process years before diagnosis, with potential applications in prevention-trial enrichment and longitudinal disease monitoring.
- 13 November 2026
- Published by Springer Nature in Research Square
Open AccessDisease aging clocks in the plasma proteome stratify risk and track preclinical progression
Aging is the strongest risk factor for most chronic diseases, yet people of the same chronological age differ in how far disease processes have advanced. Existing plasma proteomic clocks estimate chronological age, or the age of a single organ, but none targets the pathway from aging to a specific disease. Here we developed disease aging clocks by deriving the plasma proteomic composite that maximizes the age-mediated component of disease risk and applied the framework to 31 age-related diseases in 44,526 UK Biobank participants. The resulting disease age gap separated 10-year incidence up to 20-fold among individuals of the same chronological age, and each additional year of gap raised the hazard of type 2 diabetes by 24%, chronic kidney disease by 21% and Alzheimer′s disease (AD) by 17%. Among participants who went on to develop disease, the gap was larger closer to diagnosis in 19 of 20 diseases, indicating that it reports preclinical stage rather than fixed susceptibility. Across these 20 diseases, 56% of the gap was orthogonal to chronological and organ-specific clocks. Applied without refitting to Stanford Alzheimer′s Disease Research Center participants (n=501), the AD clock was elevated in AD and Lewy body disease but not Parkinson′s disease, and tracked plasma biomarkers, cognition and neuroimaging features. Disease aging clocks provide a blood-based measure of the stage of a specific aging-to-disease process years before diagnosis, with potential applications in prevention-trial enrichment and longitudinal disease monitoring.
- Open Access
- 5 November 2026
- Published by Springer Nature in Research Square
Contextual Verbal Information Modulates Low Frequency Neuronal Population Activity During Face Processing
Perception of faces is shaped by prior expectations1,2. To address how expectations modulate face processing, we recorded intracranial EEG3,4 across 2836 recording sites in 20 participants as they heard a valenced description about a person, saw that person's face, and rated their impression. Using a two-step approach, we decomposed high- (HFA; 70–170 Hz) and low-frequency (LFA; 1–8 Hz) domains into spatiotemporal motifs using consensus NMF5. Next, we constructed encoding models for each motif, on a trial-by-trial basis to identify traces of expectations during face processing using pretrained language model semantic embeddings. HFA motifs were modality-specific and tracked semantic content predominantly during the audio epoch. In contrast, the effect of valence was seen in LFA motifs, and trial-by-trial neural signals during face epoch were predicted by semantic content across distributed sites. This suggests that semantic information carried by a preceding short narrative is reflected in low-frequency neural activity during subsequent face processing. Our findings offer insights into frequency-specific contributions to how the human brain integrates prior expectations with incoming sensory input.
- 5 November 2026
- Published by Springer Nature in Research Square
Open AccessContextual Verbal Information Modulates Low Frequency Neuronal Population Activity During Face Processing
Perception of faces is shaped by prior expectations1,2. To address how expectations modulate face processing, we recorded intracranial EEG3,4 across 2836 recording sites in 20 participants as they heard a valenced description about a person, saw that person's face, and rated their impression. Using a two-step approach, we decomposed high- (HFA; 70–170 Hz) and low-frequency (LFA; 1–8 Hz) domains into spatiotemporal motifs using consensus NMF5. Next, we constructed encoding models for each motif, on a trial-by-trial basis to identify traces of expectations during face processing using pretrained language model semantic embeddings. HFA motifs were modality-specific and tracked semantic content predominantly during the audio epoch. In contrast, the effect of valence was seen in LFA motifs, and trial-by-trial neural signals during face epoch were predicted by semantic content across distributed sites. This suggests that semantic information carried by a preceding short narrative is reflected in low-frequency neural activity during subsequent face processing. Our findings offer insights into frequency-specific contributions to how the human brain integrates prior expectations with incoming sensory input.
- Open Access
- 20 October 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (11)
Distilling direct effects via conditional differential gene expression analysis
Motivation: Differential gene expression (DGE) analysis is foundational for interpreting RNA sequencing data, but it conflates direct biological effects with correlations propagated through gene co-expression. Across three RNA sequencing datasets (including a genome-scale perturb-seq experiment), we find that only a small fraction of differentially expressed genes have direct effects on the trait of interest, while the majority are undirected or passengers whose associations are mediated through other genes. Results: To distinguish direct effect genes, we introduce conditional differential gene expression (CDGE) analysis, a framework that tests for conditional rather than marginal association between each gene and the trait of interest. Implemented via the GhostKnockoff procedure with lasso regression, CDGE delivers false discovery rate control, operates on summary statistics from existing DGE pipelines, and accommodates batch effects. The genes identified by CDGE mediate the effects of most other differentially expressed genes and show stronger enrichment for known protein–protein interactions and biological pathways than DGE-identified genes. These results suggest that the field has been systematically over-interpreting DGE outputs, and that distinguishing direct from mediated effects is essential for prioritizing genes for functional follow-up and therapeutic development. Availability and implementation: To facilitate public access to knockoff-based CDGE analysis, we have developed the R package “KnockoffCDGE” as an integrated implementation, which is freely available at https://github.com/GuJQ5/KnockoffCDGE (DOI: 10.5281/zenodo.23241517).
- 20 October 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (11)
Open AccessDistilling direct effects via conditional differential gene expression analysis
Motivation: Differential gene expression (DGE) analysis is foundational for interpreting RNA sequencing data, but it conflates direct biological effects with correlations propagated through gene co-expression. Across three RNA sequencing datasets (including a genome-scale perturb-seq experiment), we find that only a small fraction of differentially expressed genes have direct effects on the trait of interest, while the majority are undirected or passengers whose associations are mediated through other genes. Results: To distinguish direct effect genes, we introduce conditional differential gene expression (CDGE) analysis, a framework that tests for conditional rather than marginal association between each gene and the trait of interest. Implemented via the GhostKnockoff procedure with lasso regression, CDGE delivers false discovery rate control, operates on summary statistics from existing DGE pipelines, and accommodates batch effects. The genes identified by CDGE mediate the effects of most other differentially expressed genes and show stronger enrichment for known protein–protein interactions and biological pathways than DGE-identified genes. These results suggest that the field has been systematically over-interpreting DGE outputs, and that distinguishing direct from mediated effects is essential for prioritizing genes for functional follow-up and therapeutic development. Availability and implementation: To facilitate public access to knockoff-based CDGE analysis, we have developed the R package “KnockoffCDGE” as an integrated implementation, which is freely available at https://github.com/GuJQ5/KnockoffCDGE (DOI: 10.5281/zenodo.23241517).
- Open Access
Unlocking Sensitive Data with SPHERE in the Age of AI
Sensitive human data underpin discoveries across medicine, biology and the social sciences, yet privacy regulation often prevents sharing them with collaborators or artificial intelligence (AI) systems. We introduce SPHERE, a model-free method that makes sensitive datasets directly usable by AI and shareable for open science as a synthetic twin, while the original records never leave the local environment. Across 33 datasets spanning five scientific domains, SPHERE protects individual privacy against adversarial re-identification attacks while preserving the data’s statistical structure: means, variances and correlations are reproduced exactly, effect size and P value in linear statistical analysis are numerically identical, nonlinear machine-learning utility is retained, and each twin is generated in seconds on a laptop. Frontier AI agents running on the twin reach the same scientific conclusions as on the original records. Analyses of the twin reproduce genome- and proteome-wide results at UK Biobank scale and recover the findings of landmark studies across three independent cohorts and consortia. The approach also extends to deep-learning embeddings across language, vision and time-series, with minimal utility loss. We make the Stanford Alzheimer’s Disease Research Center cohort openly available for the first time, as a SPHERE twin spanning nine modalities that any registered researcher can analyze without an approval process. We release SPHERE with certification of each twin’s privacy and fidelity, and an AI agent that autonomously executes research tasks on sensitive data without ever accessing it. Sensitive datasets that are currently closed to research could thus become routine inputs to open science and AI to enable key discoveries.
Open AccessUnlocking Sensitive Data with SPHERE in the Age of AI
Sensitive human data underpin discoveries across medicine, biology and the social sciences, yet privacy regulation often prevents sharing them with collaborators or artificial intelligence (AI) systems. We introduce SPHERE, a model-free method that makes sensitive datasets directly usable by AI and shareable for open science as a synthetic twin, while the original records never leave the local environment. Across 33 datasets spanning five scientific domains, SPHERE protects individual privacy against adversarial re-identification attacks while preserving the data’s statistical structure: means, variances and correlations are reproduced exactly, effect size and P value in linear statistical analysis are numerically identical, nonlinear machine-learning utility is retained, and each twin is generated in seconds on a laptop. Frontier AI agents running on the twin reach the same scientific conclusions as on the original records. Analyses of the twin reproduce genome- and proteome-wide results at UK Biobank scale and recover the findings of landmark studies across three independent cohorts and consortia. The approach also extends to deep-learning embeddings across language, vision and time-series, with minimal utility loss. We make the Stanford Alzheimer’s Disease Research Center cohort openly available for the first time, as a SPHERE twin spanning nine modalities that any registered researcher can analyze without an approval process. We release SPHERE with certification of each twin’s privacy and fidelity, and an AI agent that autonomously executes research tasks on sensitive data without ever accessing it. Sensitive datasets that are currently closed to research could thus become routine inputs to open science and AI to enable key discoveries.
- 8 August 2026
- Published by Wiley in Genetic Epidemiology
- Vol. 50 (6) , e70051
Robust Inference With Ghostknockoffs in Genome‐Wide Association Studies With Sample Relatedness
Genome‐wide association studies (GWASs) have been extensively adopted to depict the underlying genetic architecture of complex traits. Recent studies show that knockoff‐based methods can identify variants with unique, potentially causal effects on phenotypes. However, their statistical validity and effectiveness in studies with related individuals, such as the UK Biobank, remain unexplored. In this paper, we extensively evaluate a simple and effective analytical strategy that integrates GhostKnockoffs and state‐of‐the‐art marginal association tests. We show that this approach is robust to arbitrary relatedness structure as long as the input Z ‐scores are derived from valid generalized linear mixed models. This robustness also extends GhostKnockoffs to other GWASs settings, including meta‐analysis of studies with sample overlap when the input score test Z ‐scores are properly calibrated, and association test statistics beyond score tests in independent sample settings. We demonstrate the method's validity and practical utility using simulation studies and a meta‐analysis of nine European ancestral genome‐wide association studies and whole exome/genome sequencing studies for the Alzheimer's disease.
- 8 August 2026
- Published by Wiley in Genetic Epidemiology
- Vol. 50 (6) , e70051
Robust Inference With Ghostknockoffs in Genome‐Wide Association Studies With Sample Relatedness
Genome‐wide association studies (GWASs) have been extensively adopted to depict the underlying genetic architecture of complex traits. Recent studies show that knockoff‐based methods can identify variants with unique, potentially causal effects on phenotypes. However, their statistical validity and effectiveness in studies with related individuals, such as the UK Biobank, remain unexplored. In this paper, we extensively evaluate a simple and effective analytical strategy that integrates GhostKnockoffs and state‐of‐the‐art marginal association tests. We show that this approach is robust to arbitrary relatedness structure as long as the input Z ‐scores are derived from valid generalized linear mixed models. This robustness also extends GhostKnockoffs to other GWASs settings, including meta‐analysis of studies with sample overlap when the input score test Z ‐scores are properly calibrated, and association test statistics beyond score tests in independent sample settings. We demonstrate the method's validity and practical utility using simulation studies and a meta‐analysis of nine European ancestral genome‐wide association studies and whole exome/genome sequencing studies for the Alzheimer's disease.
- Open Access
- 4 August 2026
- Published by Elsevier in SSRN Electronic Journal
Plasma Proteomics Reveals Divergent Sex-Specific Senescence and Bone Biology Signatures across Neurodegenerative Diseases
Neurodegenerative diseases are usually accompanied by systemic comorbidities, including changes in bone health, but the molecular relationship between neurodegeneration, skeletal decline, and cellular senescence remains poorly understood. In this study, we investigated sex-specific changes in circulating bone- and senescence-related proteins across the spectrum of Alzheimer’s disease (AD), Lewy body degeneration (LB) and Parkinson’s disease (PD). Plasma proteomic profiling was performed on samples from 408 participants from the Stanford Alzheimer’s Disease Research Center deeply phenotyped for neurodegenerative diseases, followed by differential protein and pathway analyses. This study reveals sex-dependent alterations in bone and senescence-related circulating proteins in AD-related, PD and LB-related neurodegenerative diseases, providing insights into the complex relationship between neurodegeneration and bone health. Several candidate proteins were also associated with established plasma neurodegeneration biomarkers, particularly pTau181. Pathway analyses revealed shared mitochondrial and metabolic dysfunction across neurodegenerative diseases, with disease-specific features including vesicle trafficking disruption in AD and inflammatory-senescence pathways in LB, plus sex-divergent patterns in inflammatory signaling and bone-related pathways.
- 4 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPlasma Proteomics Reveals Divergent Sex-Specific Senescence and Bone Biology Signatures across Neurodegenerative Diseases
Neurodegenerative diseases are usually accompanied by systemic comorbidities, including changes in bone health, but the molecular relationship between neurodegeneration, skeletal decline, and cellular senescence remains poorly understood. In this study, we investigated sex-specific changes in circulating bone- and senescence-related proteins across the spectrum of Alzheimer’s disease (AD), Lewy body degeneration (LB) and Parkinson’s disease (PD). Plasma proteomic profiling was performed on samples from 408 participants from the Stanford Alzheimer’s Disease Research Center deeply phenotyped for neurodegenerative diseases, followed by differential protein and pathway analyses. This study reveals sex-dependent alterations in bone and senescence-related circulating proteins in AD-related, PD and LB-related neurodegenerative diseases, providing insights into the complex relationship between neurodegeneration and bone health. Several candidate proteins were also associated with established plasma neurodegeneration biomarkers, particularly pTau181. Pathway analyses revealed shared mitochondrial and metabolic dysfunction across neurodegenerative diseases, with disease-specific features including vesicle trafficking disruption in AD and inflammatory-senescence pathways in LB, plus sex-divergent patterns in inflammatory signaling and bone-related pathways.
- Open Access
- 13 July 2026
- Published by Springer Nature in Genome Biology
- Vol. 27 (1)
CIT-Lasso: a scalable approach beyond guilty by association for identifying causal variants from genome-wide summary statistics
We present CIT-Lasso, a framework that uses only summary statistics to identify, genome-wide, sets of variants carrying non-redundant information on a phenotype, distinguishing likely causal variants from correlated variants that are merely associated. The open-source implementation completes genome-wide analysis in under 15 min on one CPU. In simulations, it outperforms existing methods in false discovery rate control, power, and fine-mapping resolution. Applied to an Alzheimer's disease meta-analysis, it identified 82 loci, 37 beyond conventional GWAS; prior MPRA and CRISPR-Cas9 studies corroborate prioritized variants. Results on other 67 large-scale GWAS reveal the method's generalizability to make discoveries beyond conventional GWAS pipeline.
- 13 July 2026
- Published by Springer Nature in Genome Biology
- Vol. 27 (1)
Open AccessCIT-Lasso: a scalable approach beyond guilty by association for identifying causal variants from genome-wide summary statistics
We present CIT-Lasso, a framework that uses only summary statistics to identify, genome-wide, sets of variants carrying non-redundant information on a phenotype, distinguishing likely causal variants from correlated variants that are merely associated. The open-source implementation completes genome-wide analysis in under 15 min on one CPU. In simulations, it outperforms existing methods in false discovery rate control, power, and fine-mapping resolution. Applied to an Alzheimer's disease meta-analysis, it identified 82 loci, 37 beyond conventional GWAS; prior MPRA and CRISPR-Cas9 studies corroborate prioritized variants. Results on other 67 large-scale GWAS reveal the method's generalizability to make discoveries beyond conventional GWAS pipeline.
- Open Access
Disease Outcomes in Boys with ABCD1 Variants Identified by Newborn Screening for X-ALD
Objectives To determine whether boys with VUS detected through newborn screening (NBS) for adrenoleukodystrophy (ALD) develop adrenal insufficiency (aiALD) and cerebral ALD (cALD) at rates comparable to those with pathogenic variants, and to evaluate the relationship between C26:0-lysophosphatidylcholine (C26:0-LPC) levels and clinical outcomes. Methods We conducted a retrospective multicenter cohort study (2013 - 2025) across six US centers, including 201 males identified through NBS in 19 states. Variants were classified as pathogenic (n=65), likely pathogenic (n=45), or VUS (n=88). Primary outcomes were development of aiALD and cALD; secondary outcomes included C26:0-LPC levels. Statistical analyses included Kaplan-Meier, mixed-effects regression, and Cox models. Results 201 males with ABCD1 variants identified through NBS for ALD. Median age at last follow-up was 4.2 years (IQR 2.5 - 7.9). Overall, 26% developed aiALD (54% pathogenic, 16% likely pathogenic, 11% VUS), and 8% developed cALD (11%, 9%, and 4.5%, respectively). Pathogenic/likely pathogenic variants were associated with higher odds of aiALD than VUS (OR 5.8; 95% CI 2.16 - 15.58; p=0.001). At 150 months, 39% of individuals with pathogenic/likely pathogenic variants remained free of aiALD versus 85% with VUS. C26:0-LPC levels were higher in pathogenic variants and correlated with genotype (p=0.0006). Higher levels were associated with increased aiALD risk and earlier onset (HR 1.38 per 0.1 umol/L; 95% CI 1.20 - 1.59; p<0.0001). Conclusions Boys with VUS had lower rates of aiALD and lower C26:0-LPC levels than those with pathogenic variants, although some developed disease. C26:0-LPC correlates with genotype and risk, supporting its role in variant classification and risk-stratified surveillance.
Open AccessDisease Outcomes in Boys with ABCD1 Variants Identified by Newborn Screening for X-ALD
Objectives To determine whether boys with VUS detected through newborn screening (NBS) for adrenoleukodystrophy (ALD) develop adrenal insufficiency (aiALD) and cerebral ALD (cALD) at rates comparable to those with pathogenic variants, and to evaluate the relationship between C26:0-lysophosphatidylcholine (C26:0-LPC) levels and clinical outcomes. Methods We conducted a retrospective multicenter cohort study (2013 - 2025) across six US centers, including 201 males identified through NBS in 19 states. Variants were classified as pathogenic (n=65), likely pathogenic (n=45), or VUS (n=88). Primary outcomes were development of aiALD and cALD; secondary outcomes included C26:0-LPC levels. Statistical analyses included Kaplan-Meier, mixed-effects regression, and Cox models. Results 201 males with ABCD1 variants identified through NBS for ALD. Median age at last follow-up was 4.2 years (IQR 2.5 - 7.9). Overall, 26% developed aiALD (54% pathogenic, 16% likely pathogenic, 11% VUS), and 8% developed cALD (11%, 9%, and 4.5%, respectively). Pathogenic/likely pathogenic variants were associated with higher odds of aiALD than VUS (OR 5.8; 95% CI 2.16 - 15.58; p=0.001). At 150 months, 39% of individuals with pathogenic/likely pathogenic variants remained free of aiALD versus 85% with VUS. C26:0-LPC levels were higher in pathogenic variants and correlated with genotype (p=0.0006). Higher levels were associated with increased aiALD risk and earlier onset (HR 1.38 per 0.1 umol/L; 95% CI 1.20 - 1.59; p<0.0001). Conclusions Boys with VUS had lower rates of aiALD and lower C26:0-LPC levels than those with pathogenic variants, although some developed disease. C26:0-LPC correlates with genotype and risk, supporting its role in variant classification and risk-stratified surveillance.
- Open Access
Personalized Feature Statistics: Individual-Level Variant Inference under Genetic Ancestry Continuum
Genome-wide association studies (GWAS) have successfully identified numerous genetic variants associated with complex diseases. However, the extent to which the effects of these variants vary across populations of diverse ancestries remains poorly understood. Furthermore, in these contexts genetic ancestry is treated as a categorical variable, thereby oversimplifying its continuous nature and the more nuanced ways in which it can influence genetic effects on disease. Here, we propose personalized feature statistics ( PFstatistics ), a statistical framework that quantifies the importance of genetic variants to a phenotype based on each individual’s ancestry background, and profiles heterogeneous genetic effects across the genetic ancestry continuum. We demonstrate the utility of this framework through both simulations and real data analysis using sequencing data from ancestrally diverse cohorts in the Alzheimer’s Disease Sequencing Project (ADSP). We show that Alzheimer’s Disease (AD) risk variants span a spectrum from ancestry-homogeneous to ancestry-dependent effects, and that PFstatistics characterizes this spectrum at individual resolution across the ancestry continuum. PFstatistics also provides individual-level variant selection with FDR controlled at a target level, yielding distinct selection sets that vary across individuals according to their ancestry background. While demonstrated in the context of genetic ancestry, the proposed method is broadly applicable to other heterogeneity features such as environmental factors, offering a robust tool for understanding complex genetic contributions across diverse populations.
Open AccessPersonalized Feature Statistics: Individual-Level Variant Inference under Genetic Ancestry Continuum
Genome-wide association studies (GWAS) have successfully identified numerous genetic variants associated with complex diseases. However, the extent to which the effects of these variants vary across populations of diverse ancestries remains poorly understood. Furthermore, in these contexts genetic ancestry is treated as a categorical variable, thereby oversimplifying its continuous nature and the more nuanced ways in which it can influence genetic effects on disease. Here, we propose personalized feature statistics ( PFstatistics ), a statistical framework that quantifies the importance of genetic variants to a phenotype based on each individual’s ancestry background, and profiles heterogeneous genetic effects across the genetic ancestry continuum. We demonstrate the utility of this framework through both simulations and real data analysis using sequencing data from ancestrally diverse cohorts in the Alzheimer’s Disease Sequencing Project (ADSP). We show that Alzheimer’s Disease (AD) risk variants span a spectrum from ancestry-homogeneous to ancestry-dependent effects, and that PFstatistics characterizes this spectrum at individual resolution across the ancestry continuum. PFstatistics also provides individual-level variant selection with FDR controlled at a target level, yielding distinct selection sets that vary across individuals according to their ancestry background. While demonstrated in the context of genetic ancestry, the proposed method is broadly applicable to other heterogeneity features such as environmental factors, offering a robust tool for understanding complex genetic contributions across diverse populations.
Functional connectivity in self‐limited epilepsy with centrotemporal spikes increases with epilepsy duration and interictal spike exposure
Objective: To determine whether persistent exposure to interictal spikes is associated with progressive changes in functional connectivity in children with self‐limited epilepsy with centrotemporal spikes (SeLECTS). Methods: Connectivity was calculated from electroencephalograms (EEGs) of 68 children with SeLECTS and 65 age‐ and sex‐matched controls using the weighted phase lag index. First, we assessed whether connectivity increased with longer epilepsy duration, categorizing duration based on time since first seizure (less vs. greater than 6 months). Second, in a subset of 19 SeLECTS children with repeated EEGs, we assessed whether trajectory of connectivity over time differed based on persistence versus resolution of spikes. Connectivity during sleep and wakefulness was examined separately. Results: During sleep, connectivity was lowest in controls, intermediate in patients with recent onset epilepsy, and highest in those with longer epilepsy duration. Elevations in connectivity were greatest within the right occipital region at onset and became more widespread with longer epilepsy duration, especially increasing in the left temporal region. During wakefulness, connectivity in recent onset epilepsy trended lower than controls, whereas longer duration epilepsy trended higher, such that the two epilepsy groups differed significantly from each other but not from controls. In the cohort of children with repeated EEGs, patients with persistent spikes showed increasing connectivity over time in sleep, whereas those with spike resolution demonstrated decreasing connectivity over time. There were no significant changes in awake connectivity over time regardless of spike persistence or resolution. Significance: Functional connectivity in SeLECTS increases progressively with longer duration of spike exposure, suggesting that ongoing spikes drive neural network alterations. Spikes are a potential treatment target to prevent progressive brain network disruption and preserve cognitive outcomes.
Functional connectivity in self‐limited epilepsy with centrotemporal spikes increases with epilepsy duration and interictal spike exposure
Objective: To determine whether persistent exposure to interictal spikes is associated with progressive changes in functional connectivity in children with self‐limited epilepsy with centrotemporal spikes (SeLECTS). Methods: Connectivity was calculated from electroencephalograms (EEGs) of 68 children with SeLECTS and 65 age‐ and sex‐matched controls using the weighted phase lag index. First, we assessed whether connectivity increased with longer epilepsy duration, categorizing duration based on time since first seizure (less vs. greater than 6 months). Second, in a subset of 19 SeLECTS children with repeated EEGs, we assessed whether trajectory of connectivity over time differed based on persistence versus resolution of spikes. Connectivity during sleep and wakefulness was examined separately. Results: During sleep, connectivity was lowest in controls, intermediate in patients with recent onset epilepsy, and highest in those with longer epilepsy duration. Elevations in connectivity were greatest within the right occipital region at onset and became more widespread with longer epilepsy duration, especially increasing in the left temporal region. During wakefulness, connectivity in recent onset epilepsy trended lower than controls, whereas longer duration epilepsy trended higher, such that the two epilepsy groups differed significantly from each other but not from controls. In the cohort of children with repeated EEGs, patients with persistent spikes showed increasing connectivity over time in sleep, whereas those with spike resolution demonstrated decreasing connectivity over time. There were no significant changes in awake connectivity over time regardless of spike persistence or resolution. Significance: Functional connectivity in SeLECTS increases progressively with longer duration of spike exposure, suggesting that ongoing spikes drive neural network alterations. Spikes are a potential treatment target to prevent progressive brain network disruption and preserve cognitive outcomes.